CED Studienzentrum Karlshorst
  • CED studies for participants
  • Study partner for IBD studies
  • English
    • German
Select Page

ABTECT-1 Study on Ulcerative Colitis

by Pauline Lauterbach | Jan 16, 2026 | Completed, For participants

ABTECT-1 Study on Ulcerative Colitis A recent study tested ABX464, a new drug for people with moderate to severe ulcerative colitis who have not responded to standard treatments. Participants received either ABX464 or a placebo to determine if the drug can alleviate...

Recent Posts

  • Crohn’s disease: Study on the efficacy and safety of risankizumab (FORTIFY)
  • Crohn’s disease: Study on subcutaneous guselkumab (GRAVITI)
  • Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)
  • Ulcerative colitis: Combination study with guselkumab and golimumab (DUET-UC)
  • Ulcerative colitis: Study on the efficacy and safety of risankizumab

Recent Comments

No comments to show.

We look forward to receiving your contact request.



Ehrenfelsstr. 46, 10318 Berlin



Mon. - Fri. 9:00 AM - 5:00 PM



E-mail contact



+49 30 46309410

All studies are approved by an independent ethics committee and are conducted in accordance with international GCP standards.
Participation is voluntary and can be withdrawn at any time without disadvantage. Your data will be treated strictly confidentially in accordance with GDPR.

© CED Studienzentrum Berlin | Imprint | Privacy Policy | Accessibility Statement

  • Sprechstunde | Consultation
  • English
  • Deutsch (German)